The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic implications of phosphoproteomics in molecular cancer diagnostics.
 
Annika Schneider
No Relationships to Disclose
 
Julia Woortman
No Relationships to Disclose
 
Cecilia Bang Jensen
No Relationships to Disclose
 
Amirhossein Sakhteman
No Relationships to Disclose
 
Maria-Veronica Teleanu
No Relationships to Disclose
 
Peter Horak
Stock and Other Ownership Interests - Platomics
Honoraria - Roche Pharma AG; Trillium GmbH
Consulting or Advisory Role - Platomics
 
Simon Kreutzfeldt
Consulting or Advisory Role - Roche
 
Barbara Hutter
No Relationships to Disclose
 
Jennifer Huellein
No Relationships to Disclose
 
Moritz Resch
No Relationships to Disclose
 
Christoph Stange
No Relationships to Disclose
 
Chien-Yun Lee
No Relationships to Disclose
 
Olaf Witt
No Relationships to Disclose
 
David T.W. Jones
No Relationships to Disclose
 
Daniel Hübschmann
No Relationships to Disclose
 
Stefan M. Pfister
Consulting or Advisory Role - BioSkryb Genomics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Lilly (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
Patents, Royalties, Other Intellectual Property - patent on utilizing DNA methylation profiling for tumor classification; patent using nanopore sequencing for rapid tumor diagnostics
 
Wilko Weichert
Honoraria - ADC Therapeutics; Agilent; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers-Squibb; Eisai; GlaxoSmithKline; Illumina; Janssen; Lilly; Merck KGaA; MolecularHealth; MSD; Novartis; Pfizer; Roche; Siemens; Takeda
Consulting or Advisory Role - ADC Therapeutics; Agilent; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Illumina; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; MolecularHealth; Novartis; Pfizer; Roche; Siemens Healthcare Diagnostics; Takeda
Speakers' Bureau - ADC Therapeutics; Agilent; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Illumina; Johnson & Johnson/Janssen; Lilly; Merck; Merck Sharp & Dohme; MolecularHealth; Novartis; Pfizer; Roche; Roche; Siemens; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ADC Therapeutics; Agilent; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers-Squibb; Eisai; GlaxoSmithKline; Illumina; Janssen; Lilly; Merck; MolecularHealth; MSD; Novartis; Pfizer; Roche; Siemens; Takeda
 
Matthew The
No Relationships to Disclose
 
Stefan Froehling
Honoraria - Amgen; Lilly; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Illumina; Roche
Research Funding - AstraZeneca (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Lilly; PharmaMar; Roche
 
Bernhard Kuster
Stock and Other Ownership Interests - MSAID; OmicScouts
Consulting or Advisory Role - Covant Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim